ESJ seeks submissions to a new Collection, focused on understanding and combating resistance mechanisms in advanced prostate cancer. We hope it can serve to highlight new research on this topic including ADT and taxane chemotherapy resistance, tumor microenvironment impacts, biomarkers, metastasis mechanisms, targeted therapies, and enhanced immunotherapies.
Meet the Guest EditorsHolger Erb, PhD: Dresden University of Technology, Germany
Dr Holger Erb is a seasoned molecular biologist with over a decade of experience in prostate cancer (PCa) research who has successfully published multiple therapy resistance-related publications in recent years. Currently, he serves as deputy laboratory manager at “Klinik und Poliklinik für Urologie Universitätsklinikum Dresden” (Germany) and leads his research group in translational uro-oncology. Holger Erb holds a PhD in molecular pathology and finished his Venia Legendi in 2022. His expertise includes prostate cancer, androgen receptor signaling, molecular biology, and therapy resistance.
Jacob Orme, MD, PhD: Mayo Clinic, US
Jacob Orme, MD, PhD, is a genitourinary medical oncologist and translational physician scientist who works in the clinic and the laboratory to make cancer care better for his patients. Dr Orme discovered the source and consequence of soluble PD-L1 in immunotherapy-resistant cancers as well as a novel biomarker "switch" in advanced highly-resistant prostate cancers. These discoveries have led to the development of multiple new experimental therapeutics and clinical trials. Dr Orme has received awards from Mayo Clinic, the Minnesota Society of Clinical Oncology, the National Institutes of Health, and the Prostate Cancer Foundation to support his work.